ciclesonide has been researched along with Viremia* in 1 studies
1 other study(ies) available for ciclesonide and Viremia
| Article | Year |
|---|---|
The SARS-CoV-2 E protein induces Toll-like receptor 2-mediated neonatal lung injury in a model of COVID-19 viremia that is rescued by the glucocorticoid ciclesonide.
SARS-CoV-2 viremia is associated with increased acute lung injury (ALI) and mortality in children and adults. The mechanisms by which viral components in the circulation mediate ALI in COVID-19 remain unclear. We tested the hypothesis that the SARS-CoV-2 envelope (E) protein induces Toll-like receptor (TLR)-mediated ALI and lung remodeling in a model of neonatal COVID-19. Neonatal C57BL6 mice given intraperitoneal E protein injections revealed a dose-dependent increase in lung cytokines [interleukin 6 ( Topics: Acute Lung Injury; Animals; Child; COVID-19; Endothelial Cells; Glucocorticoids; Humans; Lipopolysaccharides; Mice; Mice, Inbred C57BL; SARS-CoV-2; Toll-Like Receptor 2; Toll-Like Receptor 4; Toll-Like Receptors; Transforming Growth Factor beta; Viral Envelope; Viremia | 2023 |